Find Funding Opportunities

Request Information RFI) NIH CTSA Neuroscience Research Notice Number: NOT-NS-11-007 Key Dates Release Date: March 18, 2011 Responses Due By:  assure consideration, comments must received May 20, 2011 Issued National Institute Neurological Disorders Stroke NINDS) National Center Research Resources NCRR) NIH Blueprint Neuroscience Research http://neuroscienceblueprint.nih.gov Purpose NIH Clinical Translational Science Award program CTSA) Neuroscience Research Trans-NIH Workgroup seeking public comment potential programs facilitate neuroscience research using existing new research resources. CTSA program supports national consortium medical research institutions committed speeding translation laboratory discoveries treatments patients, engaging communities clinical research efforts, training new generation clinical translational researchers http://www.ctsaweb.org/). this RFI, neuroscience research defined broadly the conduct basic, clinical, translational research relevant conditions diseases the nervous system. Neuroscience research employ interdisciplinary research teams include neuroscience researchers areas such as, not limited to, addiction, anatomy, behavioral health, biostatistics, economics, engineering, epidemiology, ethics, information systems technology, minority health, mental health, molecular developmental neurobiology, neurogenetics, neuroimaging, physics, substance disorders neuro-related fields clinical medicine.  this RFI, neuro-related fields clinical medicine generate neuroscience researchers include, are limited to, anesthesia, behavioral mental health, cardiovascular medicine, cognitive neuroscience, complementary alternative medicine, developmental disorders the nervous system, emergency medicine, geriatrics, internal medicine, military medicine, neurocritical care, neuroendocrinology, neurology, neurooncology, neuroradiology, neurosurgery, occupational environmental health, ophthalmology, otolaryngology, pediatrics/child neurology, physical medicine rehabilitation, psychiatry, sleep medicine, substance disorders. RFI aims gather information critical gaps, challenges, potential strategies close gaps resolve challenges order develop coordinate resources neuroscience research using CTSA infrastructure. Resources research include--but not limited to--team science, clinical trials infrastructure, collaborative networks, education training, biomedical informatics, clinical research units/centers, community engagement research, ethics, evaluation, novel clinical translational methodologies, pilot collaborative translational clinical studies, public-private partnerships, regulatory knowledge support, translational technologies. Background CTSA program complements programs the NIH Institutes works cooperation other NIH activities other relevant trans-NIH activities. goal the institutional Clinical Translational Science Award CTSA) program to transform local, regional national environment clinical translational science, thereby increasing efficiency speed clinical translational research. transformation be achieved creating academic home, can a center, department, institute, comprising faculty programs integrate clinical translational science across multiple departments, schools, clinical research institutes hospitals. CTSA expected include faculty able conduct original research, develop graduate postgraduate training curricula lead programs integrate clinical translational science across multiple departments, schools, clinical research institutes hospitals. more information, please http://www.ctsaweb.org. Definitions:  the purpose this initiative, clinical research comprises studies trials human subjects meeting NIH definition the PHS 398 instructions see: http://grants.nih.gov/grants/funding/phs398/phs398.pdf). Translational research includes areas translation. is process applying discoveries generated during research the laboratory, in preclinical studies, the development trials studies humans. second area translation concerns research aimed clinical trials other prospective studies, retrospective studies, observational studies, dissemination implementation enhance adoption best practices the community. Cost-effectiveness prevention treatment strategies also an important part translational science. Bidirectional communication work processes integral each these areas translational research. comparative effectiveness research prevention treatment strategies also important part translational science. Information Requested RFI seeks information critical gaps challenges potential approaches resolve in order enhance resources neuroscience research using infrastructure available through CTSA institutional, regional, the national consortium. Ideas both short-term 6 months-1 year) long-term 2-5 years) approaches develop coordinate neuroscience research research resources welcome. Members the scientific community, scientific organizations, healthcare professionals, patient advocates, the public invited respond any, all the following: Challenges — Describe critical gaps other challenges neuroscience research the CTSAs might address. Challenges be the level clinical translational research, clinical trials, participant recruitment amp; retention, special populations, team science collaborative networking, infrastructure, workforce resources, information systems technology, methodology, interventions, the execution, implementation, evaluation programs. Potential Solutions — Describe you believe be most innovative approaches address challenges.  NIH seeking input advice the following items.  Please consider commenting any the items are relevant your work and/or research. Challenges:  1.  are critical gaps in, other challenges to, advancing neuroscience research through team science your perspective may include or of following: 1) researcher, 2) patients/consumer individual advocacy group, 3) health care provider, 4) type health care professional, 5) administrator, 6) information systems technology worker, 7) health care payer, 8) research funding organization, 9) private organization, 10) regulatory agency? 2.  Identify critical gaps other challenges CTSAs address facilitate clinical and/or translational neuroscience research the CTSAs’ institutional, regional, and/or national consortium level. 3.  Aspects neuroscience research you think been impacted the NIH’s investment CTSAs.   Please consider commenting  any the CTSA functions resources devoted education training, biomedical informatics, clinical research units/centers, community engagement  research, ethics, evaluation, novel clinical translational methodologies, pilot collaborative translational clinical studies, public-private partnerships, regulatory knowledge support, translational technologies. 3a. have any these functions resources utilized advance neuroscience research? Feel free give particular examples might serve models others. 3b. have any these functions resources contributed the dissemination the outcomes neuroscience research researchers, clinical practice, patients community groups, policymakers? 4.  Drivers the decisions researchers, new treatment developers, drug, device diagnostic manufacturers participate multicenter neuroscience clinical trials conducted within CTSA Consortium infrastructure. 5.  are critical gaps other challenges constrain neuroscience clinical trials within CTSAs? are unique challenges highly impact participant recruitment retention especially among participants special populations with rare diseases these clinical trials? 6.  are barriers conducting assessing outcomes comparative effectiveness research neuroscience the CTSA institutional, regional, and/or national consortium level? 7.  your perspective, please describe interactions between CTSAs basic clinical researchers are neuroscientists, clinicians, nurses, allied health professionals, complementary alternative medicine experts, economists, engineers, epidemiologists, informaticians, methodologists, statisticians interests translational neuroscience research addressing: 7a. Communication, partnership, participation research teams related planned / ongoing studies examining development novel treatments diagnostics, rehabilitation, quality life, symptom identification/symptom management, palliative care, end life, behavioral mental health illness such but limited addiction, depression, post-traumatic stress disorders cognitive impairments such but limited mild cognitive impairments MCI), memory impairments resulting but limited brain injury, Alzheimer’s vascular diseases, autism, pain, mobility impairments resulting but limited arthritis, bone muscular diseases, spinal cord injury, stroke. 7b. Early career mid-career research training needs. 8.  Comment the most challenging barriers engaging private sector including for-profit non-for-profit organizations interact the CTSA Consortium. 9.  are critical gaps challenges the execution, implementation, evaluation CTSA programs advance neuroscience research? 10.  there issues NIH should consider the development team science advance neuroscience research? Potential Solutions:  1.  are potential approaches close critical gaps resolve challenges you described under Challenges Section” advance neuroscience  research through team science your perspective may include or of following: 1) researcher, 2) patients/consumer individual advocacy group, 3) health care provider, 4) type health care professional, 5) administrator, 6) information systems technology, 7) health care payers, 8) research funding organization, 9) private organization, 10) regulatory agency? 2.  CTSAs be utilized conduct preclinical studies early phase clinical trials phase 0/phase I/phase II) CNS drug development. Please comment the level target identification developmental methods. 3.  CTSAs might effectively contribute basic, clinical, and/or translational neuroscience research the CTSA institutional, regional, and/or national consortium level. 4.  the various neuroscience institutes other funding organizations might leverage value productivity their own investments interacting the CTSAs. 5.  can CTSAs better conduct assess outcomes comparative effectiveness research neuroscience the CTSA institutional, regional, and/or national consortium level? 6.  most effective approaches ensure continued dissemination the outcomes neuroscience research collection review multistakeholder input the CTSA institutional, regional, and/or national consortium level. 7.  can infrastructure the CTSAs best leveraged take advantage advances neuroscientific tools such as, not limited to, neuroimaging, neurogenomics, proteomics, metabolomics biomarker development, early phase studies assess proof biologic activity novel treatments?   8.  CTSAs more effectively contribute developing sustaining translational neuroscience research education, training, workforce. 9.  can infrastructure the CTSAs leveraged advance neuroscience translational discoveries the development evidence-based medicine  any the following research areas: a)      Autism b)      Behavioral health c)      Cancer d)      Cardiovascular and/or autonomic system e)      Cerebrovascular conditions events f)       Complementary Alternative Medicine CAM) g)      Concussions, Traumatic Brain Injury TBI), and/or Blast Injury h)      Genomics i)        Implementation science j)       Information dissemination k)       Mental health l)        Minority underserved populations m)     Neurocritical care n)      Neurodegenerative disorders o)      Neurodevelopmental disorders normative brain development p)      Neuroimaging q)      Neurological disorders Infant, adolescent, adult, and/or elderly r)       Neuroplasiticity s)      Neuro-related devices, information systems technology, other technologies t)       Neuro- related physical medicine rehabilitation u)      Neurotherapeutics v)       Neuro-related disorders occupational environmental health w)      Nursing x)       Pain y)       Patient centered outcomes comparative effectiveness research CER) z)       Peripheral nerve disorders aa)    Post Traumatic Stress Disorder PTSD) bb)    Sensory impairments disorders cc)     Sleep dd)    Spinal cord injury SCI) ee)    Substance disorders ff)      research areas listed 10.  can investigators working translational neuroscience relevant infants, children, adolescents, and/or adults, including elderly, CTSA resources infrastructure? 11.  CTSAs encourage developmental perspective, across lifespan, ongoing translational neuroscience research, applicable. 12.  can infrastructure the CTSAs best leveraged facilitate translation findings basic research behavioral social neuroscience effective interventions – pharmacological, behavioral devices – improve health? 13.  Given recent decline pharmaceutical company funding nervous system research development, can CTSAs re-invigorate neuroscience drug development? 14.  what purpose(s) you utilize CTSA Consortium Neuroscience Thematic Special Interest Group support research career development efforts? RESPONSES assure consideration, comments must received May 20, 2011. Individuals, groups, organizations interested commenting how Clinical Translational Science Awards CTSAs) advance neuroscience research, outlined this RFI, submit comments this RFI. Responses this RFI must submitted electronically using wed-based format http://www.ninds.nih.gov/funding/rfi-nihctsa-neuroscience.htm. Comments be publicly available, including any personally identifiable confidential business information they contain.  Trade secrets should be submitted.  Inquiries further information contact: Walter Koroshetz: koroshetzw@mail.nih.gov Rosemarie Filart:  filartr@mail.nih.gov Jerry Doyle:  doylejj@mail.nih.gov Request Information RFI) for planning purposes only is a solicitation applications an obligation the part the United States U.S.) Government provide support any ideas identified response it.  Please note the U.S. Government not pay the preparation any information submitted for use that information. Footnotes: the purposes this RFI, definition comparative effectiveness research CER) adhere that adopted the Federal Coordinating Council given http://www.hhs.gov/recovery/programs/cer/cerannualrpt.pdf: Comparative effectiveness research the conduct synthesis research comparing benefits harms different interventions strategies prevent, diagnose, treat monitor health conditions real world” settings. purpose this research to improve health outcomes developing disseminating evidence-based information patients, clinicians, other decision-makers, responding their expressed needs, which interventions most effective which patients under specific circumstances. provide information, comparative effectiveness research must assess comprehensive array health-related outcomes diverse patient populations subgroups. Defined interventions compared include medications, procedures, medical assistive devices technologies, diagnostic testing, behavioral change, delivery system strategies. research necessitates development, expansion, use a variety data sources methods assess comparative effectiveness actively disseminate results.

Notice Intent Publish Funding Opportunity Announcement Induced Pluripotent Stem Cell iPSC) Resources promoting Translational Research Advancements Neurodegenerative Diseases U24) Notice Number: NOT-NS-11-011 Key Dates Release Date: February 15, 2011 Issued National Institute Neurological Disorders Stroke NINDS) Purpose National Institute Neurological Disorders Stroke NINDS) intends publish Funding Opportunity Announcement FOA) nbsp;to promote continued development publically available, well characterized induced pluripotent stem cell iPSC) research resources will enable encourage collaborative research among academic industry investigators ultimately accelerate basic science discoveries therapeutic development late-onset neurodegenerative diseases. Notice being provided allow potential applicants sufficient time develop meaningful collaborations responsive projects.  FOA expected be published spring 2011 an expected receipt date early summer 2011. FOA utilize Research-related Resource cooperative agreement U24) activity code. Details the planned Funding Opportunity Announcement FOA) provided below. Research Initiative Details Notice encourages investigators have expertise somatic cell reprogramming, neurodegenerative disease biology, translational research, drug discovery the creation publically available, well characterized iPSC resources neurodegenerative diseases consider applying this new Funding Opportunity Announcement FOA).  December 2010, Workshop convened NINDS review technologies resources developed iPSC consortia investigators funded NINDS through American Recovery Reinvestment Act ARRA). http://www.ninds.nih.gov/funding/areas/neurodegeneration/2nd_iPSC_Conso… )  nbsp; Given insights recommendations provided the workshop, the challenges still be addressed applying iPSC resources the pre-clinical drug discovery process, NINDS recognizes unique opportunity bring academic industry researchers together share expertise drug development, stem cell biology neurodegenerative disease biology. APPLICATIONS NOT BEING SOLICITED THIS TIME. Inquiries Please direct inquiries to: Margaret Sutherland, PhD Program Director, Neurodegeneration Cluster Division Extramural Research National Institute Neurological Disorders Stroke 6001 Executive Boulevard, Room 2222 Bethesda, MD 20892-9531 Phone: 301) 496-5680 Email: sutherlandm@ninds.nih.gov nbsp;

Applications the Jointly Sponsored Ruth L. Kirschstein National Research Service Award Institutional Predoctoral Training Program the Neurosciences T32) Not Accepted 2011 Notice Number: NOT-NS-11-009 Key Dates Release Date: January 21, 2011 Issued National Institute Neurological Disorders Stroke NINDS) National Institute Aging NIA) National Institute Alcohol Abuse Alcoholism NIAAA) Eunice Kennedy Shriver National Institute Child Health Human Development NICHD) National Institute General Medical Sciences NIGMS) National Institute Mental Health NIMH) Purpose Funding Opportunity Announcement FOA) the Jointly Sponsored Ruth L. Kirschstein National Research Service Award Institutional Predoctoral Training Program Neurosciences JSPTPN; PAR-10-116) expired. purpose this Notice to inform extramural community a new FOA this program not reissued submission applications the 25, 2011 receipt date. NIH institutes above committed the continuation a broad-based, early stage predoctoral training program neurosciences, plan issue new FOA this program time receipt applications May 2012. Inquiries Direct questions this Notice to: Stephen J. Korn, Ph.D. Chair, JSPTPN Steering Committee Director Training Career Development NIH/NINDS e-mail: korns@ninds.nih.gov

NHLBI Announces Participation PA-10-056, Mentored Research Scientist Development Award Parent K01)” Notice Number: NOT-HL-11-114 Key Dates Release Date: January 14, 2011 Issued National Human Genome Research Institute NHGRI), http://www.nhgri.nih.gov/) National Heart, Lung, Blood Institute NHLBI), http://www.nhlbi.nih.gov) National Institute Aging NIA), http://www.nia.nih.gov/) National Institute Alcohol Abuse Alcoholism NIAAA), http://www.niaaa.nih.gov/) National Institute Allergy Infectious Diseases NIAID), http://www.niaid.nih.gov/) National Institute Arthritis Musculoskeletal Skin Diseases NIAMS), http://www.niams.nih.gov/) National Institute Biomedical Imaging Bioengineering NIBIB), http://www.nibib.nih.gov/) Eunice Kennedy Shriver National Institute Child Health Human Development NICHD), http://www.nichd.nih.gov/) National Institute Deafness Other Communication Disorders NIDCD), http://www.nidcd.nih.gov) National Institute Diabetes Digestive Kidney Diseases NIDDK), http://www.niddk.nih.gov/) National Institute Drug Abuse NIDA), http://www.nida.nih.gov/) National Institute Environmental Health Sciences NIEHS), http://www.niehs.nih.gov) National Institute Mental Health NIMH), http://www.nimh.nih.gov/) National Institute Neurological Disorders Stroke NINDS), http://www.ninds.nih.gov/) National Institute Nursing Research NINR), http://ninr.nih.gov/) National Center Complementary Alternative Medicine NCCAM), http://www.nccam.nih.gov/) National Center Research Resources NCRR), http://www.ncrr.nih.gov/) Purpose Notice to inform potential applicants the NHLBI announces participation, effective February 12, 2011, PA-10-056, Mentored Research Scientist Development Award Parent K01).” NHLBI seeks career training applications the following focused research areas: Highly innovative epidemiological research elucidates mechanisms, etiology, pathogenesis, prevention, diagnosis treatment heart, lung, blood diseases sleep disorders. Biostatistics research leading the development new methods designing analyzing clinical studies, including clinical trials, epidemiologic genetics studies heart, lung, blood diseases sleep disorders. Comparative effectiveness research involves comparison screening, diagnostic, preventive treatment strategies heart, lung, blood diseases sleep disorders using appropriate methods randomized controlled trials the analysis electronic medical records. research project proposed must relevant the mission the NHLBI must focused one more the target areas listed above. Training should ensure candidates develop relevant research skills, gain knowledge state-of-the art concepts, advanced methods experimental approaches will allow to become independent investigators play leading roles these areas. Professionals quantitative e.g., mathematics, statistics, economics, computer science, imaging science, informatics, physics, chemistry) engineering backgrounds wish gain fundamental knowledge develop research skills biomedicine, bioengineering, bioimaging, behavioral research should apply the Mentored Quantitative Research Career Development Award K25). The NHLBI also participates the K08 K23 programs focus research training clinical scientists clinically trained professionals wish conduct basic patient-oriented research respectively. NHLBI does support projects primarily focused malignancy-related research. Studies address mechanistic correlation between cancer i.e., lung cancer) primary pulmonary diseases be considered within mission the NHLBI. Applications vaccine development be considered outside NHLBI’s focused intent this Funding Opportunity Announcement FOA). Applications respiratory pathogens be considered within NHLBI’s intent this FOA studies focus the host immune response. potential overlapping areas interest shared the NHLBI other Institutes/Centers the NIH include myeloproliferative myelodysplastic disorders, hematological malignancies resulting disruptions hematopoiesis, the of hematopoietic stem cell transplantation other cellular therapies. Therefore, applicants strongly encouraged contact NHLBI before submitting application determine NHLBI programmatic appropriateness this FOA. other aspects the FOA remain unchanged. Inquiries Lorraine M. Silsbee, M.H.S. Division Cardiovascular Sciences National Heart, Lung, Blood Institute 6701 Rockledge Drive, MSC 7936 Bethesda, MD 20892-7936 Express mail zip: 20817) Telephone: 301) 435-0709 FAX: 301) 480-1455 Email: silsbeeL@nhlbi.nih.gov Jane D. Scott, ScD, MSN, FAHA Director, Office Research Training Career Development, Division Cardiovascular Sciences DCVS - responding all NHLBI programmatic Divisions) National Heart, Lung, Blood Institute NHLBI), NIH Rockledge II, 8138, 6701 Rockledge Drive Bethesda, Maryland 20892-7940 Telephone: 301) 435-0535 Email: scottj2@nhlbi.nih.gov

Notice Correction the Non-AIDS Related Application Due Dates PAR-11-031, Brain Disorders the Developing World: Research Across Lifespan R21) Notice Number:  NOT-TW-11-007 Key Dates Release Date:   December 22, 2010 Issued Fogarty International Center FIC) National Institute Aging NIA) National Institute Alcohol Abuse Alcoholism NIAAA) Eunice Kennedy Shriver National Institute Child Health Human Development NICHD) National Institute Drug Abuse NIDA) National Institute Environmental Health Sciences NIEHS) National Institute General Medical Sciences NIGMS) National Institute Mental Health NIMH) National Institute Neurological Disorders Stroke NINDS) National Institute Nursing Research NINR) National Institute Minority Health Health Disparities NIMHD) Office Dietary Supplements ODS) Autism Speaks www.autismspeaks.org) Purpose purpose this Notice to inform scientific community the Non-AIDS Related Application Due Dates PAR-11-031, Brain Disorders the Developing World: Research Across Lifespan R21), published November 12, 2010, incorrectly listed January 10, 2010, January 10, 2011, January 10, 2012 5:00 PM local time applicant organization.  correct Non-AIDS Related Application Due Dates January 10, 2011, January 10, 2012, January 13, 2013 5:00 PM local time applicant organization. other aspects the funding opportunity announcement remain same. Inquiries Please direct inquiries to: Kathleen Michels, Ph.D. Program Director Division International Training Research Fogarty International Center 31 Center Drive, MSC-2220 Building 31, Room B2-C39 Bethesda, MD 20892-2220 Telephone:  301-496-1653 Fax:  301-402-0779 Email:  brainfic@nih.gov

Collaborative Research Computational Neuroscience CRCNS) Innovative Approaches Science Engineering Research Brain Function R01] Notice Number:  NOT-NS-11-006 Key Dates Release Date: December 20, 2010 Receipt Dates: February 16, 2011, November 2, 2011 November 2, 2012   Related Notices NSF 11-505 http://www.nsf.gov/pubs/2011/nsf11505/nsf11505.htm) Issued National Science Foundation NSF) National Institute Neurological Disorders Stroke NINDS) National Institute Mental Health NIMH) National Institute Drug Abuse NIDA) National Institute Deafness Other Communication Disorders NIDCD) National Eye Institute NEI) National Institute Biomedical Imaging Bioengineering NIBIB) National Institute Alcohol Abuse Alcoholism NIAAA) Eunice Kennedy Shriver National Institute Child Health Human Development NICHD) National Center Complementary Alternative Medicine NCCAM) Federal Ministry Education Research Bundesministerium für Bildung und Forschung, BMBF), Germany http://www.bmbf.de/) Purpose Notice announces re-issue a joint initiative, Collaborative Research Computational Neuroscience CRCNS), among seven National Science Foundation NSF) Directorates Offices DOs), nine participating National Institutes Health NIH) Institutes Centers ICs). CRCNS announcement released under NSF 11-505 http://www.nsf.gov/pubs/2011/nsf11505/nsf11505.htm).  announcement supersedes NSF 08-514 NSF 09-60: Collaborative Research Computational Neuroscience CRCNS) – Innovative Approaches Science Engineering Research Brain Function.  German Federal Ministry Education Research Bundesministerium für Bildung und Forschung, BMBF http://www.bmbf.de/) now formal partner this program, along the NSF the NIH.  NIH, CRCNS now affiliated the NIH Blueprint Neuroscience Research http://neuroscienceblueprint.nih.gov). Computational neuroscience provides theoretical foundation a rich set technical approaches understanding complex neurobiological systems, building the theory, methods, findings computer science, neuroscience, numerous disciplines.  Through CRCNS program, participating NSF DOs, NIH ICs BMBF support innovative interdisciplinary collaborative research make significant advances the understanding structures functions the nervous system, mechanisms underlying nervous system disorders, computational strategies used the nervous system. participating agencies recognize need research focuses integrating computational models methods neuroscience.  solicitation designed encourage new collaborations this interface.  Appropriate scientific areas investigations those are currently supported NSF NIH, related the missions the agencies.  participating this broadly based program cooperation between agencies, NIH focus creating new research teams biomedical quantitative scientists explore questions directly relevant the missions participating NIH ICs. Three classes proposals be considered response this solicitation: Research proposals - describing new collaborative research projects US-German Research Proposals - describing international collaborative research projects be funded parallel US German agencies Data Sharing Proposals - enable sharing data other resources Appropriate scientific areas investigations those related the mission participating funding agencies. Questions concerning particular project’s focus, direction relevance a participating funding agency should addressed the appropriate person the list agency contacts the NSF Program Solicitation NSF 11-505, http://www.nsf.gov/pubs/2011/nsf11505/nsf11505.htm). computational research supported under program must impact on, relate biological processes, optimally generate hypotheses are testable biological studies.  is expected that: 1) applications include collaborations among computational and/or modeling experts, theorists, experimental neuroscientists; 2) collaborations involve dynamic and, possibly, protracted period model theory development refinement, intense interaction among scientists engineers different disciplines; 3) development testing new models theories provide framework the design experiments the generation new hypotheses can help reveal mechanisms underlying normal disease states the nervous system, 4) development distribution professional quality software tools e.g., modeling algorithms analytic tools). Award Information Award sizes research projects expected range approximately 100,000 250,000 per year direct costs, durations three five years.  awards be the smaller end this range; award exceed 250,000 per year direct costs.  Applicants strongly discouraged requesting greater budgets are necessary the activities being proposed. is estimated data sharing projects range approximately 25,000 100,000 cumulative award size a one- three-year project. Estimated program budget, number awards average award size duration subject the availability funds. Upon conclusion the review process, meritorious applications be recommended funding either participating NSF DOs NIH ICs, the option the agencies, the applicant.  Data sharing proposals be funded only NSF. Subsequent grant administration procedures be accordance the individual policies the awarding agency. Proposal Preparation Submission Instructions Applications submitted response this program announcement/solicitation should prepared submitted accordance the general guidelines contained the NSF Grant Proposal Guide GPG).  Applications must submitted the NSF, to NIH.  complete text the GPG available electronically the NSF Web Site at: http://www.nsf.gov/publications/pub_summ.jsp?ods_key=gpg. Applicants reminded identify program announcement number 11-505) the program announcement block the NSF Cover Sheet Proposal the National Science Foundation.  Compliance this announcement critical determining relevant proposal processing guidelines.  Failure submit information delay processing. Budgetary Information Cost sharing not required NSF proposals submitted under Program Solicitation. Budgets should include travel funds the PI team members attend annual CRCNS Principal Investigators' meeting. NIH Process those proposals are selected potential funding participating NIH ICs, PI be required resubmit proposal an NIH-approved format directly the Center Scientific Review http://www.csr.nih.gov/) the NIH.  PIs invited resubmit NIH receive further information resubmission procedures the NIH. applicant not allowed increase proposed budget change scientific content the application the resubmission the NIH. applications where principal investigators at different institutions, applicants be expected utilize Multiple Principal Investigator option the NIH http://grants.nih.gov/grants/multi_PI/) appropriate.  NIH applications be entered the NIH IMPAC II system. results the review be presented the involved IC's National Advisory Councils the second level review. Subsequent the Council reviews, NIH ICs make funding determinations selected awards be made.  Subsequent grant administration procedures NIH awardees, including those related New Early Stage Investigators http://grants.nih.gov/grants/new_investigators/) be accordance the policies NIH. Applications selected NIH funding use NIH R01 funding mechanism. Please note applications submitted the NSF February 16, 2011, selected potential funding the participating NIH ICs, have extremely short conversion time.  applicants be notified the end March, 2011, the resubmission be due the NIH April 6, 2011.  Applicants wish give Grants Office advance notice this timetable. Inquiries Written telephone inquiries encouraged.  Please the NSF program announcement names contact information each the participating NSF DOs and/or NIH ICs http://www.nsf.gov/crcns. .

Pre-application Meeting the Network Excellence Neuroscience Clinical Trials NEXT) Notice Number: NOT-NS-11-005 Key Dates Release Date: December 7, 2010 Issued National Institute Neurological Disorders Stroke NINDS) Purpose National Institute Neurological Disorders Stroke NINDS) hold pre-application meeting regarding Request Applications RFA) Clinical Research Sites the Network Excellence Neuroscience Clinical Trials RFA-NS-11-008), the Clinical Coordinating Center RFA-NS-11-009), for Data Coordinating Center RFA-NS-11-010). meeting intended be informative all prospective applicants consider responding these Funding Opportunity Announcements FOAs). NINDS Program Review Staff provide overview the network initiative will explain specific aspects the FOAs a brief presentation followed a question answer session. Participation the meeting, although encouraged, optional not required application submission.   Questions prior and during meeting be submitted e-mail NEXT@ninds.nih.gov. Research Initiative Details Title: Pre-application Meeting the NINDS NEXT Initiative Location: 6001 Executive Boulevard, Rockville, MD, Conference Room 2172 Date: Friday, December 17, 2010 Time: 12:00 PM - 1:00 PM GMT - 05:00) ET U.S. Canada). Teleconference: 1-800-988-9536 (U.S. only) Participant Code:     54989 Webinar: https://webmeeting.nih.gov/r59127599/ Access: Anyone has URL the meeting enter room Prospective applicants interested attending meeting person asked provide advance contact below) names, contact information, institutional affiliation. informal registration optional is primarily planning purposes. Please advised the NINDS not cover expenses attend meeting. Inquiries Please direct inquiries to: Crina Frincu, PhD National Institute Neurological Disorders Stroke 6001 Executive Boulevard, Room 2192 Rockville, MD 20852 Telephone: 301-496-5446 Email: NEXT@ninds.nih.gov

Pre-application Meeting RFA-NS-11-005 - Clinical Data Coordinating Center(s) Parkinson's Disease Biomarkers Identification Network PD-BIN) U01) Notice Number:  NOT-NS-11-003 Key Dates Release Date:   November 24, 2010 Pre-Application Meeting Date: December 17, 2010 Issued National Institute Neurological Disorders Stroke NINDS) Purpose National Institute Neurological Disorders Stroke NINDS) hold pre-application meeting regarding RFA-NS-11-005 http://grants.nih.gov/grants/guide/rfa-files/RFA-NS-11-005.html), Clinical Data Coordinating Center(s) Parkinson’s Disease Biomarkers Identification Network PD-BIN) U01), which prospective applicants invited. is intended explain goals objectives this initiative answer questions prospective applicants. Participation this meeting neither required nor necessary a successful application. Details Meeting: Title: Pre-application Meeting RFA-NS-11-005 When: Friday, December 17th, 2010; 3:00pm-4:00pm Time Zone: GMT - 05:00) Eastern Time US Canada) Website: https://webmeeting.nih.gov/pdbinccc-dccrfa/ Telephone information audio): Conference number US Participants): 1-866-692-4538 Participant Code: 2145501 Non-US participants, please email contact listed below call-in information your specific location be provided. Please email questions advance, wished, the below contact. While effort be to include questions, is possible not will addressed during meeting due time constraints. Inquiries questions further information, contact: Katrina Gwinn MD National Institute Neurological Disorders Stroke 6001 Executive Blvd Room 2143 Bethesda MD 20892 Telephone: 301-496-5745 Fax: 301-502-1501 Email: gwinnk@ninds.nih.gov

Notice Intent Publish Limited Competition Program Announcement Applications Rare Diseases Clinical Research Consortia RDCRC) the Rare Diseases Clinical Research Network U54) Notice Number:  NOT-NS-11-004 Key Dates Release Date:   November 24, 2010 Issued National Institute Neurological Disorders Stroke NINDS) Office Rare Diseases Research ORD) Purpose National Institute Neurological Disorders Stroke NINDS), the NIH Office Rare Diseases Research ORDR), intend publish Funding Opportunity Announcement FOA) solicit applications research rare diseases via Rare Diseases Clinical Research Network.  FOA be limited competition available only the current American Recovery Reinvestment Act ARRA)-supported Rare Disease Clinical Research Consortia awardees.  Notice being provided allow potential applicants sufficient time develop meaningful collaborations responsive projects.  FOA expected be published the winter 2011 a receipt date the spring 2011. FOA utilize U54 activity code. Details the planned FOA provided below. Research Initiative Details Notice encourages investigators expertise insights the area rare neurological disorders begin consider applying this limited competition FOA.  objective to facilitate clinical research rare diseases through support for: 1) collaborative clinical research rare diseases, including longitudinal studies individuals rare diseases, clinical studies and/or phase I, II II/III trials; 2) training clinical investigators rare diseases research; 3) pilot demonstration projects; 4) access information related rare diseases basic clinical researchers, academic practicing physicians, patients, the lay public.  total project period an application submitted response this FOA not exceed 3 years. APPLICATIONS NOT BEING SOLICITED THIS TIME. Inquiries Please direct inquiries to: Randall R. Stewart, PhD Program Director National Institute Neurological Disorders Stroke 6001 Executive Blvd., Room 2135 Bethesda, MD 20892 Telephone: 301-496-1917 Fax:  301-402-1501 stewartr@ninds.nih.gov

Correction RFA-CA-10-017, quot;Scientific Meetings Creating Interdisciplinary Research Teams Basic Behavioral Social Science Research R13)," Order Simplify Submission Requirements Notice Number:  NOT-CA-11-001 Key Dates Release Date: November 18, 2010 Related Notices None Issued NIH Basic Behavioral Social Science Opportunity Network OppNet; http://oppnet.nih.gov/) and, member institutes, centers, offices) National Cancer Institute NCI) National Center Minority Health Health Disparities NCMHD) nbsp; National Eye Institute NEI) National Heart, Lung, Blood Institute NHLBI) National Human Genome Research Institute NHGRI) National Institute Aging NIA) National Institute Alcohol Abuse Alcoholism NIAAA) National Institute Allergy Infectious Diseases NIAID) National Institute Arthritis Musculoskeletal Skin Diseases NIAMS) National Institute Biomedical Imaging Bioengineering NIBIB) Eunice Kennedy Shriver National Institute Child Health Human Development NICHD) National Institute Deafness Other Communication Disorders NIDCD) National Institute Dental Craniofacial Research NIDCR) National Institute Diabetes Digestive Kidney Diseases NIDDK) National Institute Drug Abuse NIDA) National Institute Environmental Health Sciences NIEHS) National Institute General Medical Sciences NIGMS) National Institute Mental Health NIMH) National Institute Neurological Disorders Stroke NINDS) National Institute Nursing Research NINR) National Library Medicine NLM) Fogarty International Center FIC) National Center Complementary Alternative Medicine NCCAM) National Center Research Resources NCRR) Office AIDS Research OAR) Office Behavioral Social Sciences Research OBSSR) Office Dietary Supplements ODS) Office Disease Prevention ODP)  Office Research Women’s Health ORWH) Purpose purpose this Notice to correct RFA-CA-10-017, quot;Scientific Meetings Creating Interdisciplinary Research Teams Basic Behavioral Social Science Research R13)," eliminating requirement a quot;Permission-to-Submit Letter" the appropriate NIH Institute Center IC) Conference Grant Contact. such quot;Permission-to-Submit Letter" required order submit application.  Thus, Section IV.2 Content Form Application Submission RFA-CA-10-017, last item the block subtitled quot;Required Components" changed from: quot;PHS398 Cover Letter File, including Permission-to-Submit Letter appropriate IC Conference Grant Contact" quot;PHS398 Cover Letter File." other aspects RFA-CA-10-017 remain unchanged. Inquiries Please direct inquiries to: Kara L. Hall, Ph.D. Behavioral Research Program Division Cancer Control Population Sciences National Cancer Institute NCI) 6130 Executive Boulevard, EPN Room 4078, MSC 7326 Bethesda, MD 20892-7326 U.S. Postal Service express regular mail) Rockville, MD 20852 non-USPS delivery) Telephone: 301-594-9056 Fax: 301-480-2087 Email: hallka@mail.nih.gov Lis Nielsen, Ph.D. Division Behavioral Social Research National Institute Aging NIA) 7201 Wisconsin Avenue, 533 Bethesda, MD 20892-9205 Telephone: 301-402-4156 Fax: 301-402-0051 Email: nielsenli@nia.nih.gov Mariela C. Shirley, Ph.D. Division Epidemiology Prevention Research DEPR) National Institute Alcohol Abuse Alcoholism NIAAA) 5635 Fishers Lane, Room 2086, MSC 9304 Bethesda, MD 20892-9304 U.S. Postal Service express regular mail) Rockville, MD 20852-1705 non-USPS delivery) Telephone:  301-443-9787 Fax: 301-443-8614 Email:  shirleym@mail.nih.gov